With 4933 cases, we found no increased risk within 21-day risk interval across vaccines and by subgroups. However, an elevated risk emerged within 42-day risk interval among individuals <65 years who received co-administration of Pfizer-BioNTech bivalent vaccine and influenza vaccine on the same day; relative incidence (RI) was 2.14 (95% CI, 1.02-4.49). Among those who also had history of SARS-CoV-2 infection, RI was 3.94 (95% CI, 1.10-14.16). After chart review, RIs were 2.35 (95% CI, 0.98-5.65) and 4.33 (95% CI, 0.98-19.11), respectively. Among individuals <65 years who received Moderna bivalent vaccine and had history of SARS-CoV-2 infection, RI was 2.62 (95% CI, 1.13-6.03) before chart review and 2.24 (95% CI, 0.78-6.47) after chart review.
Our study showed an increased point estimate for the risk of ischemic stroke in a risk interval of 1–42 days only among those aged <65 years who received their PfizerBioNTech bivalent vaccine and influenza vaccine on the same day, although not statistically significant. This finding is unique and may be attributed to differences in the study design compared to previous studies.
First, our study employed a calendar-based observation period spanning from September 1, 2022, to March 31, 2023. This extended timeframe enabled us to use a longer risk window of 1–42 days following vaccination in addition to the risk interval of 1–21 days in previous studies. Second, we did not exclude individuals with a history of ischemic stroke, but we did apply criteria to increase the likelihood that ischemic stroke events during the study period represented a new ischemic stroke episode. Nevertheless, it is possible that there was interaction between bivalent vaccination and history of ischemic stroke. Furthermore, in subgroup analyses, we considered the influence of history of SARS-CoV-2 infection. SARS-CoV-2 infection is associated with an increased risk of ischemic stroke, and risk factors for SARS-CoV-2 infection may overlap with risk factors for ischemic stroke. There is potential interaction between bivalent vaccination and history of SARS-CoV-2 infection.
The finding that the point estimate for the risk of ischemic stroke was elevated among individuals aged <65 years but not among individuals aged ≥65 years is also biologically plausible. This may be due to the relatively heightened immune response and subsequent inflammation in the younger age group versus the older age group, and the fact that inflammation has been shown to be associated with an increased risk of ischemic stroke.
I just got the Autumn booster - which was the “new” Pfizer vaccine (U.K.) - does anyone know, is this the updated one that covers the variants that are currently in circulation?
Did you get much side effects?I had the Phizer one a week ago. It says on the documents I was given that it's XBB 1.5 which is the most updated version available anywhere, I think.
I had the Phizer one a week ago. It says on the documents I was given that it's XBB 1.5 which is the most updated version available anywhere, I think.
Very mild again.Did you get much side effects?
Previously I've had very mild side effects from Pfizer but I don't know if that'll be the same for the updated one?
In conclusion, people reporting PVS after covid-19 vaccination in this study are highly symptomatic, have poor health status, and have tried many treatment strategies without success. As PVS is associated with considerable suffering, there is an urgent need to understand its mechanism to provide prevention, diagnosis, and treatment strategies.
ALERT
If you are buying LFTs, check that they are not expired.
I still ask people who are mixing widely to check with an LFT before they see me and provide an LFT if necessary.
We had lots of free ones from when the pandemic was very active but are running out so ordered some from Boots.
Hilda Bastian said:A massive funding boost from Project NextGen enables 3 phase 2b trials of next generation Covid vaccines to start in the US next year, each with 10,000 participants. Another US vaccine is also heading into phase 2 next year. And could “lifelong,” or even decades-long, immunity against Covid be possible? A vaccine aiming for that is heading into its first clinical trial next year, also funded through Project NextGen.
In this update, there is also new clinical trial data for 3 next generation Covid vaccines. Those highlights and more below, are broken down into news from US Project NextGen, and 3 categories of next-generation Covid vaccines (definitions below).